Thursday, 27 Feb 2020

You are here

Pegloticase Infusion Reactions Largely Seen in Non-Responders

The introduction of intravenous pegloticase (PEG) in 2010 was felt by many to be a major advance in the treatment of patients with severe, refractory tophaceous gout.  But for some, concerns over infusion reactions and safety have limited its use.

Calabrese and colleagus have analyzed patient data from clinical trials to assess the frequency or severity of infusion reactions and compared rates of infusion reactions (IRs) in responders and nonresponders

IRs from two RCTs of pegloticase were evaluated and categorized as anaphylaxis, hypersensitivity, or other. Serum levels of tryptase and total hemolytic complement (CH50) were evaluated at the time of all IRs. Frequency of IRs by each category was evaluated in all subjects, responders or nonresponders to pegloticase.

In total there were 113 IRs amongh 1695 infusions; with a rate of 6.7%. Only 6/113 met criteria for anaphylaxis (overall anaphylaxis risk 0.35%), according to the National Institute of Allergy and Infectious Disease/Food and Allergy and Anaphylaxis Network (NIAID/FAAN) criteria.  Hypersensitivity was seen in 53, with only one feature of anaphylaxis criteria.

Infusion reactions were higher in nonresponders compared to responders, whether pegloticase was given every 2 weeks (9.8% nonresponders vs 0.5% in responders) or every 4 weeks IV (12.2% vs 2.6%).

There were no differences among in types of IRs with regard to clinical course or biochemical evidence of immune activation determined by CH50 or tryptase levels.

Thus, IRs were common in nonresponders. Anaphylaxis was not associated with immune activation or a more severe course. The authors stated that the safety prescribing rule to discontinue PEG if uric acid rises to >6 mg/dL, is important to avoid and decrease the frequency of IRs.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare: